Loading resource…

Department of Pulmonary Medicine, Integrated Hospital Institute, Cleveland Clinic, Cleveland, OH, USA
Interstitial lung disease (ILD) remains a significant challenge in respiratory medicine, with high mortality rates and a substantial burden on patients and healthcare systems. Despite advancements in diagnostics and treatment over the past decade, ILD continues to be a progressive disorder for many. The editorial emphasizes the heterogeneity of ILD and the importance of individualized management strategies based on disease phenotyping. It also outlines the evolving understanding of ILD, including new guidelines and emerging therapeutic options that may improve patient outcomes.
No account needed